Glucagon-like peptide-1 receptor agonists and risk of substance use disorders
Posted 29 May 2026
Dr Lisa Devine discusses a study examining the risk of substance use disorders and adverse related clinical events following glucagon-like peptide-1 receptor agonist initiation in people with no history, or with a pre-existing history, of substance use disorders, respectively.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.